Afatinib (trade name: Gilotrif) is an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2) for the treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC). Afatinib has been approved by the U.S Food and Drug Administration on July 12, 2013.
Product Name: Afatinib
Synonyms: BIBW 2992
CAS Number: 850140-72-6
Molecular Weight:  485.9446
Molecular Formula:  C24H25ClFN5O3
Purity (HPLC): ≥99%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.